Announced today that Bruker Corporation and Agilent Technologies.

have entered right into a definitive asset purchase contract pursuant to which Bruker will acquire specific product lines of Varian. Agilent and Bruker announced that their transaction is at the mercy of customary closing circumstances and regulatory approvals, and is likely to close soon after Agilent completes its acquisition of Varian . Supply Varian, Inc.. Bruker to obtain certain products of Varian Related StoriesEMBL researchers make use of mass spectrometry data to investigate effects of cancer drugsExperts to highlight fresh diagnostic products, tools to recognize heart attacks at 2015 AACC Annual MeetingNew data analysis platform reveals major flaw in GC-MS processVarian, Inc.Freedland, M.D., of The Brady Urological Institute, Johns Hopkins Medicine, Baltimore, and co-workers conducted a study to at least one 1) identify clinical factors that are associated with elevated risk for prostate cancer-specific death pursuing radical prostatectomy, and 2) to recognize men who are at high risk and may benefit from aggressive treatment and the concerning identify those guys who are in low risk and can be safely observed. The analysis included 379 males who experienced undergone radical prostatectomy between 1982 and 2000 and who got a biochemical recurrence. The common follow-up after surgery was 10.3 years. Related StoriesMD Anderson study reveals why chemotherapy medications not effective for most pancreatic cancer patientsFDA grants accelerated acceptance for Tagrisso to take care of individuals with advanced NSCLCViralytics enters into scientific trial collaboration agreement with MSDThe researchers found that PSA doubling period , pathological Gleason rating , and time from medical procedures to biochemical recurrence had been all significant risk elements for time to prostate-specific loss of life.